CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
对这些近期获批和新兴疗法相关毒性进行最佳管理，对于最大化临床获益并推动其在常规临床实践中的广泛采用至关重要。
引言：过去5年中，多种新药已获批用于治疗复发/难治性多发性骨髓瘤（RRMM），其临床应用日益广泛。临床医师需要熟悉这些药物相关的常见毒性，以及需要特定管理和支持治疗的新型毒性。综述范围：本文回顾过去5年获批的RRMM药物相关常见毒性，包括抗CD38单克隆抗体Isatuximab、抗体偶联药物Belantamab mafodotin、双特异性抗体Teclistamab、嵌合抗原受体（CAR）T细胞产品Idecabtagene vicleucel和Ciltacabtagene autoleucel、选择性核输出抑制剂Selinexor及药物-肽偶联物Melflufen；还讨论RRMM在研药物相关毒性，包括其他双特异性抗体、BCL-2抑制剂Venetoclax及Cereblon E3连接酶调节剂Iberdomide和Mezigdomide。研究者通过PubMed检索已发表文献，并搜索相关会议摘要，检索上述药物名称或类别与“骨髓瘤”相关的资料。专家观点：妥善管理近期获批和在研疗法的毒性，对于最大限度发挥临床获益并推动其在常规实践中广泛应用至关重要。本文总结当前建议和指南，并提供有关支持治疗需求的专家见解。
INTRODUCTION: Multiple new drugs have been approved over the past 5 years for the treatment of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely used. Clinicians need to familiarize themselves with common toxicities associated with these drugs and with novel toxicities requiring specific management and supportive care.
AREAS COVERED: We review common toxicities associated with agents approved for RRMM in the past 5 years, including the anti-CD38 monoclonal antibody isatuximab, the antibody-drug conjugate belantamab mafodotin, the bispecific antibody teclistamab, the chimeric antigen receptor (CAR) T cell products idecabtagene vicleucel and ciltacabtagene autoleucel, the selective inhibitor of nuclear export compound selinexor, and the drug-peptide conjugate melflufen, as well as toxicities associated with emerging agents for RRMM including additional bispecific antibodies, the BCL-2 inhibitor venetoclax, and the cereblon E3 ligase modulators iberdomide and mezigdomide.
We searched the published literature using PubMed, plus congress abstracts, for the above list of drug names or classes and 'myeloma.' EXPERT OPINION: Optimal management of toxicities associated with these recently approved and emerging therapies will be critical in maximizing clinical benefit and aiding widespread adoption in routine clinical practice.
We summarize current recommendations and guidelines and provide expert insights into supportive care requirements.
MEMBER ACCOUNT
登录成功会直接打开下一页。
